Chang‐Fang Chiu

机构：China Medical University, China Medical University Hospital

发表论文 107 篇 · 总被引 3154 次 · h-index 22

代表论文

• Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025 · The Lancet · 被引 323)
• Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. (2024 · Journal of Clinical Oncology · 被引 148)
• Short-term effect of internet-delivered mindfulness-based stress reduction on mental health, self-efficacy, and body image among women with breast cancer during the COVID-19 pandemic (2022 · Frontiers in Psychology · 被引 39)
• Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer (2023 · JAMA Oncology · 被引 28)
• Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses. (2025 · Journal of Clinical Oncology · 被引 11)
• Antithymocyte globulin plus post-transplant cyclophosphamide combination as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation for hematological malignancies (2022 · International Journal of Hematology · 被引 11)